SEIZURE - EUROPEAN JOURNAL OF EPILEPSY is a leading journal published by W B SAUNDERS CO LTD, specializing in the field of epilepsy and seizure disorders. Since its inception in 1992, this journal has committed itself to advancing research and understanding in neurology, achieving a respectable 2023 impact factor reflected by its Q2 rankings in Medicine (miscellaneous), Neurology, and Clinical Neurology categories. With an impressive Scopus ranking that places it in the top 35% of journals in Neuroscience and Neurology, SEIZURE is dedicated to promoting high-quality research and clinical studies that offer insights into epilepsy management and treatment. Although not an open-access journal, it maintains a diverse array of original articles, reviews, and case studies catering to academicians, medical professionals, and students looking to expand their knowledge on epilepsy. This journal is pivotal for those seeking to stay abreast of the latest trends, therapies, and findings in the neuroclinical landscape.

Neurodegenerative Diseases, published by KARGER, is a prominent academic journal dedicated to advancing the field of neurology and neuroscience. With an ISSN of 1660-2854 and E-ISSN 1660-2862, this journal serves as a vital platform for researchers, professionals, and students engaged in the exploration of neurodegenerative disorders from various perspectives, including clinical applications and therapeutic interventions. Spanning two decades since its inception in 2004 and set to converge in 2024, it has steadily built a reputation within the academic community, achieving a commendable Q2 ranking in clinical neurology and Q3 in general neurology according to the 2023 category quartiles. The journal boasts an impressive Scopus rank of 114/400 (71st percentile) in clinical neurology and 58/192 (70th percentile) in neuroscience neurology. While not classified as open access, the publication provides critical insights into the latest research and developments, making it an essential resource for anyone dedicated to understanding and combating neurodegenerative diseases.

ACTA NEUROLOGICA BELGICA is a leading academic journal published by Springer Heidelberg, dedicated to advancing the field of neurology and medicine. With an ISSN of 0300-9009 and E-ISSN 2240-2993, this journal has been a vital resource since its inception, contributing significantly to neurological research and clinical practice. It holds a respectable impact factor with categories spanning from Q2 in Medicine (miscellaneous) to Q3 in Neurology (clinical) as of 2023, indicating its prominence in the scientific community. The journal's extensive coverage since 1959 enhances its historical relevance, while its ongoing publication until 2024 ensures the latest developments are readily accessible. Researchers and practitioners can benefit from its rigorous peer-reviewed articles, which are crucial for staying current in this rapidly evolving discipline. As a scholarly platform, ACTA NEUROLOGICA BELGICA plays a pivotal role in disseminating knowledge and fostering innovation in neurology, making it a must-read for professionals, students, and anyone involved in the field.

Archives of Neuroscience is a multidisciplinary journal dedicated to advancing the field of neuroscience through the publication of original research articles, review papers, and case studies. Published by BRIEFLAND, this journal aims to bridge the gap between neuroscience research and clinical applications, fostering a deeper understanding of brain function, neurological disorders, and potential therapeutic approaches. With an ISSN of 2322-3944 and an E-ISSN of 2322-5769, Archives of Neuroscience serves as an essential platform for researchers, professionals, and students alike, encouraging open access to knowledge and insights that drive innovation in the field. Although coverage was discontinued in Scopus from 2016 to 2017, the journal continues to uphold rigorous standards of academic excellence, making it a valuable resource for the neuroscience community seeking to explore and disseminate new findings. The journal is committed to providing timely access to research tools and findings that are crucial for informed decision-making in both academic and clinical settings.

Archives of Epilepsy is a pioneering academic journal dedicated to advancing the field of epilepsy research and clinical practice. Published by GALENOS PUBL HOUSE in Turkey, this Open Access journal has embraced the principle of unrestricted access since its inception in 2012, allowing researchers, healthcare professionals, and students from around the world to engage with cutting-edge findings in neuropathology. With a focus on clinical and neuroscience aspects of neurology, the journal occupies a significant position in the academic landscape, currently ranked in the Q4 quartile in both Neurology and Clinical Neurology categories as of 2023. Though it faces challenges in its Scopus rankings with a current percentile of 2nd in Medicine - Neurology (Clinical) and 1st in Neuroscience - Neurology, it offers a valuable platform for emerging studies. The journal's commitment to fostering a comprehensive understanding of epilepsy is crucial, as it facilitates broader discourse on effective treatments and patient care strategies. We invite researchers and practitioners to explore the impactful articles published in the Archives of Epilepsy and contribute to an evolving dialogue that strives to improve outcomes for individuals affected by epilepsy.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

European Journal of Paediatric Neurology, published by Elsevier Science Ltd, is a premier academic journal dedicated to advancing the field of paediatric neurology. With its ISSN 1090-3798 and E-ISSN 1532-2130, this journal serves as a vital resource for researchers, clinicians, and students alike, focusing on the latest findings and innovative treatments in paediatric neurological disorders. The journal has established itself as a leading publication in its field, achieving a Q1 classification in Pediatrics, Perinatology and Child Health, and holding a reputable Q2 status in Clinical Neurology as of 2023. Positioned within the top 88th percentile in Pediatrics and the 76th percentile in Clinical Neurology according to Scopus ranks, it publishes rigorous peer-reviewed articles that contribute significantly to clinical practice and research. Although not open access, the journal provides vital insights into the complexities of neurological conditions affecting the pediatric population, making it an essential tool for scholars and professionals striving to improve child health outcomes. With a publication trajectory spanning from 1997 to 2024, it continues to be at the forefront of paediatric neurological research, inspiring innovation and collaboration in the scientific community.

Epilepsi is an esteemed academic journal dedicated to advancing the field of epilepsy research and treatment, published by KARE PUBL. With its open access model established since 2017, the journal ensures that vital research findings are easily accessible to a global audience, thereby fostering collaboration and knowledge sharing among researchers, healthcare professionals, and students. The journal focuses on a comprehensive range of topics within neurology, including clinical studies, therapeutic advancements, and innovative approaches to epilepsy management. Located in Istanbul, Turkey, Epilepsi aims to bridge the gap between research and practice, enhancing understanding and patient care for individuals affected by epilepsy. Its commitment to high-quality, peer-reviewed content makes it a significant resource for anyone involved in epilepsy research or clinical practice.

Clinical Parkinsonism & Related Disorders is a prominent open-access journal published by Elsevier, focused on advancing the understanding and treatment of Parkinson's disease and related neurological conditions. Since its inception in 2019, this journal has aimed to provide a platform for high-quality research, review articles, and clinical studies dedicated to elucidating the complexities of Parkinsonism and its comorbidities. With an E-ISSN of 2590-1125, it has swiftly established its role in the field of clinical neurology, currently ranked in the Q3 quartile for clinical neurology and Q4 for cellular and molecular neuroscience. While its Scopus rankings reflect a competitive landscape, occupying the 241st position in clinical neurology and the 83rd in neuroscience, the journal remains committed to fostering scholarly dialogue and supporting innovative research. Researchers, clinicians, and students will find valuable insights within its pages, contributing to ongoing discourse and the pursuit of effective therapeutic strategies. Access to all articles has been made available since 2019, emphasizing the journal's mission to disseminate knowledge widely and enhance accessibility in the scientific community.

JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.